Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$26.89
-1.98-6.86%
At close: -
$26.89
0.000.00%
After Hours: Apr 4, 4:00 PM EDT
Comments
Loading...
Crinetics Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:CRNX | Benzinga
Crinetics Pharmaceuticals Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Crinetics Pharmaceuticals Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Stifel
Citizens Capital Markets
Jefferies
HC Wainwright & Co.
JMP Securities
1calculated from analyst ratings
Analyst Ratings for Crinetics Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/25/2025 | Buy Now | — | Stifel | Alex Thompson42% | → $60 | Initiates | → Buy | Get Alert |
| 02/28/2025 | Buy Now | — | Citizens Capital Markets | Jonathan Wolleben63% | $92 → $91 | Maintains | Market Outperform | Get Alert |
| 02/04/2025 | Buy Now | — | Wolfe Research | Andy Chen36% | — | Initiates | → Peer Perform | Get Alert |
| 01/22/2025 | Buy Now | — | Jefferies | Dennis Ding16% | → $55 | Upgrade | Hold → Buy | Get Alert |
| 01/13/2025 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao51% | $81 → $81 | Reiterates | Buy → Buy | Get Alert |
| 12/16/2024 | Buy Now | — | JMP Securities | Jonathan Wolleben63% | $87 → $87 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 11/14/2024 | Buy Now | — | Citigroup | David Lebovitz64% | $70 → $74 | Maintains | Buy | Get Alert |
| 11/13/2024 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao51% | $69 → $81 | Maintains | Buy | Get Alert |
| 09/27/2024 | Buy Now | — | JMP Securities | Jonathan Wolleben63% | $80 → $80 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 09/16/2024 | Buy Now | — | Cantor Fitzgerald | Josh Schimmer52% | $90 → $90 | Reiterates | Overweight → Overweight | Get Alert |
| 08/09/2024 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao51% | $60 → $69 | Maintains | Buy | Get Alert |
| 08/09/2024 | Buy Now | — | Oppenheimer | Leland Gershell67% | $74 → $73 | Reiterates | Outperform → Outperform | Get Alert |
| 07/09/2024 | Buy Now | — | JP Morgan | Jessica Fye66% | $47 → $54 | Maintains | Overweight | Get Alert |
| 07/02/2024 | Buy Now | — | Piper Sandler | Yasmeen Rahimi56% | $97 → $97 | Maintains | Overweight | Get Alert |
| 06/28/2024 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao51% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 06/04/2024 | Buy Now | — | JMP Securities | Jonathan Wolleben63% | $80 → $80 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 06/04/2024 | Buy Now | — | Oppenheimer | Leland Gershell67% | $55 → $74 | Maintains | Outperform | Get Alert |
| 06/04/2024 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao51% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 05/23/2024 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao51% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 05/23/2024 | Buy Now | — | Baird | Brian Skorney40% | $52 → $62 | Maintains | Outperform | Get Alert |
| 05/23/2024 | Buy Now | — | Morgan Stanley | Jeffrey Hung52% | $50 → $70 | Maintains | Overweight | Get Alert |
| 05/14/2024 | Buy Now | — | Cantor Fitzgerald | Josh Schimmer52% | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 05/10/2024 | Buy Now | — | JMP Securities | Jonathan Wolleben63% | $80 → $80 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 05/10/2024 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao51% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 05/07/2024 | Buy Now | — | Piper Sandler | Yasmeen Rahimi56% | $56 → $97 | Maintains | Overweight | Get Alert |
| 03/28/2024 | Buy Now | — | JMP Securities | Jonathan Wolleben63% | $80 → $80 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 03/20/2024 | Buy Now | — | Oppenheimer | Leland Gershell67% | $54 → $55 | Maintains | Outperform | Get Alert |
| 03/20/2024 | Buy Now | — | JMP Securities | Jonathan Wolleben63% | $60 → $80 | Maintains | Market Outperform | Get Alert |
| 03/20/2024 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao51% | $50 → $60 | Maintains | Buy | Get Alert |
| 03/20/2024 | Buy Now | — | JonesTrading | Lina Kaminski20% | $52 → $56 | Maintains | Buy | Get Alert |
| 03/19/2024 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao51% | → $50 | Reiterates | Buy → Buy | Get Alert |
| 03/13/2024 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao51% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 03/13/2024 | Buy Now | — | Oppenheimer | Leland Gershell67% | $48 → $54 | Reiterates | Outperform → Outperform | Get Alert |
| 03/08/2024 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao51% | $42 → $50 | Maintains | Buy | Get Alert |
| 03/06/2024 | Buy Now | — | Citigroup | David Lebovitz64% | → $68 | Initiates | → Buy | Get Alert |
| 03/04/2024 | Buy Now | — | Cantor Fitzgerald | Josh Schimmer52% | $50 → $65 | Maintains | Overweight | Get Alert |
| 02/29/2024 | Buy Now | — | JMP Securities | Jonathan Wolleben63% | $50 → $60 | Maintains | Market Outperform | Get Alert |
| 02/29/2024 | Buy Now | — | Oppenheimer | Leland Gershell67% | $46 → $48 | Maintains | Outperform | Get Alert |
| 02/29/2024 | Buy Now | — | Baird | Brian Skorney40% | $45 → $52 | Maintains | Outperform | Get Alert |
| 02/02/2024 | Buy Now | — | Cantor Fitzgerald | Josh Schimmer52% | $50 → $50 | Reiterates | Overweight → Overweight | Get Alert |
| 01/16/2024 | Buy Now | — | Morgan Stanley | Jeffrey Hung52% | → $50 | Initiates | → Overweight | Get Alert |
| 12/19/2023 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao51% | $42 → $42 | Reiterates | Buy → Buy | Get Alert |
| 12/19/2023 | Buy Now | — | Cantor Fitzgerald | Josh Schimmer52% | $50 → $50 | Reiterates | Overweight → Overweight | Get Alert |
| 12/04/2023 | Buy Now | — | Cantor Fitzgerald | Josh Schimmer52% | → $50 | Reiterates | Overweight → Overweight | Get Alert |
| 11/20/2023 | Buy Now | — | JP Morgan | Jessica Fye66% | → $35 | Reinstates | → Overweight | Get Alert |
| 10/24/2023 | Buy Now | — | Cantor Fitzgerald | Charles Duncan71% | $52 → $50 | Assumes | → Overweight | Get Alert |
| 09/14/2023 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao51% | → $33 | Reiterates | Buy → Buy | Get Alert |
| 09/11/2023 | Buy Now | — | Oppenheimer | Leland Gershell67% | $40 → $46 | Maintains | Outperform | Get Alert |
| 09/11/2023 | Buy Now | — | Baird | Brian Skorney40% | $43 → $45 | Maintains | Outperform | Get Alert |
| 09/11/2023 | Buy Now | — | Evercore ISI Group | Maneka Mirchandaney25% | $41 → $48 | Maintains | Outperform | Get Alert |
| 09/11/2023 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao51% | → $33 | Reiterates | Buy → Buy | Get Alert |
| 08/31/2023 | Buy Now | — | Oppenheimer | Leland Gershell67% | → $40 | Initiates | → Outperform | Get Alert |
| 08/22/2023 | Buy Now | — | Cantor Fitzgerald | Charles Duncan71% | → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 08/11/2023 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao51% | → $33 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2023 | Buy Now | — | JMP Securities | Jonathan Wolleben63% | $43 → $42 | Maintains | Market Outperform | Get Alert |
| 08/09/2023 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao51% | $35 → $33 | Maintains | Buy | Get Alert |
| 06/22/2023 | Buy Now | — | Cantor Fitzgerald | Charles Duncan71% | → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 06/20/2023 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao51% | → $35 | Reinstates | Buy → Buy | Get Alert |
| 06/15/2023 | Buy Now | — | JMP Securities | Jonathan Wolleben63% | → $43 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 06/08/2023 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao51% | → $35 | Reiterates | Buy → Buy | Get Alert |
| 05/05/2023 | Buy Now | — | JMP Securities | Jonathan Wolleben63% | $41 → $43 | Maintains | Outperform | Get Alert |
| 05/05/2023 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao51% | → $35 | Reiterates | → Buy | Get Alert |
| 04/24/2023 | Buy Now | — | Piper Sandler | Yasmeen Rahimi56% | → $56 | Initiates | → Overweight | Get Alert |
| 03/30/2023 | Buy Now | — | Baird | Brian Skorney40% | → $48 | Initiates | → Outperform | Get Alert |
| 03/01/2023 | Buy Now | — | JMP Securities | Jonathan Wolleben63% | $50 → $41 | Maintains | Market Outperform | Get Alert |
| 03/01/2023 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao51% | → $35 | Reiterates | → Buy | Get Alert |
| 05/26/2022 | Buy Now | — | SVB Leerink | Joseph Schwartz65% | $36 → $39 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Crinetics Pharmaceuticals (CRNX) stock?
The latest price target for Crinetics Pharmaceuticals (NASDAQ:CRNX) was reported by Stifel on March 25, 2025. The analyst firm set a price target for $60.00 expecting CRNX to rise to within 12 months (a possible 123.13% upside). 25 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Crinetics Pharmaceuticals (CRNX)?
The latest analyst rating for Crinetics Pharmaceuticals (NASDAQ:CRNX) was provided by Stifel, and Crinetics Pharmaceuticals initiated their buy rating.
When was the last upgrade for Crinetics Pharmaceuticals (CRNX)?
The last upgrade for Crinetics Pharmaceuticals Inc happened on January 22, 2025 when Jefferies raised their price target to $55. Jefferies previously had a hold for Crinetics Pharmaceuticals Inc.
When was the last downgrade for Crinetics Pharmaceuticals (CRNX)?
There is no last downgrade for Crinetics Pharmaceuticals.
When is the next analyst rating going to be posted or updated for Crinetics Pharmaceuticals (CRNX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Crinetics Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Crinetics Pharmaceuticals was filed on March 25, 2025 so you should expect the next rating to be made available sometime around March 25, 2026.
Is the Analyst Rating Crinetics Pharmaceuticals (CRNX) correct?
While ratings are subjective and will change, the latest Crinetics Pharmaceuticals (CRNX) rating was a initiated with a price target of $0.00 to $60.00. The current price Crinetics Pharmaceuticals (CRNX) is trading at is $26.89, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.